Macrophages In Developmental Programming Of Reproductive Health
Funder
National Health and Medical Research Council
Funding Amount
$532,386.00
Summary
Programming of reproductive health in women begins long before sexual maturity. Development during childhood, puberty and adulthood produces a fully functional reproductive system capable of conceiving, gestating and nurturing a child. This project will investigate the role of immune cells known as macrophages in the reproductive system, and investigate how their disruption might influence developmental programming and have lifetime consequences for the reproductive health of the individual.
Facilitating Endometrial Receptivity To Improve Pregnancy Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$734,252.00
Summary
The womb prepares itself in each menstrual cycle for pregnancy and the implantation of an embryo. In some women, the endometrium may not prepare itself adequately and this can lead to infertility. We have identified small RNA that may be useful in predicting which women are not adequately prepared for implantation and may be used to develop treatments for infertile women, for which there are currently no treatments.
Interferon Epsilon, A Key Cytokine In The Pathophysiology Of The Female Reproductive Tract Mucosa
Funder
National Health and Medical Research Council
Funding Amount
$793,303.00
Summary
The female reproductive tract is a complex environment, which permits pregnancy but protects against infections, all under the influence of hormones and the resident microbial flora. We have discovered a novel protein called interferon epsilon that acts on cells in the female reproductive tract to regulate protection against infections. We aim to discover how this new protein works and will determine its therapeutic potential in infections and inflammatory diseases affecting women's health.
The Role Of Primordial Follicle Activation In Premature Ovarian Failure
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
As women age, both the quality and quantity of their eggs decline and their chances of conceiving plummets. Premature ovarian failure (POF) is a disease of infertility, diagnosed in 3% of all women, defined by the early onset of menopause before age 40. Our poor understanding of the factors that regulate female egg supply remains a major limitation in treating POF. I will study key factors responsible for controlling egg number, with practical implications for POF diagnosis and treatment.
Follicle-stimulating hormone (FSH) is vital for egg development, female fertility and health, and is widely used in assisted reproduction technology. But high levels of FSH are associated with premature infertility and menopause, and may lead to diseases like ovarian cancer. Understanding the biological pathways activated by elevated FSH may lead to new treatments for infertility and ovarian diseases (eg. cancer), as well as advancing new strategies for contraception.
Leveraging Women’s Health Data Resources To Reduce Chronic Disease Risk And Extend Healthspan
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Chronic diseases, such as osteoporosis and asthma, pose serious risks for Australian women. Reproductive health is central to women’s use of health services across life and is linked with the risk of chronic diseases. This research will build on two decades of linked data in Australia’s leading study of women’s health. It aims to guide development of women’s use of reproductive and maternal health services as an opportunity to prevent chronic diseases and improve long-term health.
Cumulus Cell Invasive Migration: Clearing A Path For The Oocyte
Funder
National Health and Medical Research Council
Funding Amount
$409,684.00
Summary
Ovulation is the process by which the egg is released from a female�s ovary, but it is not known how this process is controlled. We found that cells surrounding the egg are motile and similar to cancer cells; thus we hypothesize that this enables the egg to _invade� its way out of the ovary. We will test this idea in mice and determine whether similar processes are happening in women. The results will provide new information about how to stop ovulation and aid women who experience infertility.
Exploitation Of Unique Growth Factors To Develop New Products For Infertility Treatment
Funder
National Health and Medical Research Council
Funding Amount
$132,525.00
Summary
Infertility comes at an enormous social and financial cost to Australian society; infertility is a major psychological burden on young couples and the technologies used to treat infertility, such as in vitro fertilisation (IVF), require expensive drugs to stimulate the ovary. The cost of these drugs to Medicare is expected to exceed $100 million p.a. over the next decade. A reproductive technology, which has always shown great potential to elevate some of this burden, is oocyte (egg) in vitro ma ....Infertility comes at an enormous social and financial cost to Australian society; infertility is a major psychological burden on young couples and the technologies used to treat infertility, such as in vitro fertilisation (IVF), require expensive drugs to stimulate the ovary. The cost of these drugs to Medicare is expected to exceed $100 million p.a. over the next decade. A reproductive technology, which has always shown great potential to elevate some of this burden, is oocyte (egg) in vitro maturation (IVM), which drastically reduces the use-cost of drugs and the stress to patients. However, oocyte IVM has been slow to live up to its potential and the technology is still not in widespread clinical practice, mainly due to disappointing success rates in women. We have been studying oocyte IVM in animals for many years, and have recently made a significant technological breakthrough, improving success rates by ~50%. In this field, a 50% increase in efficiency is substantial and has significant clinical and commercial application. Currently, we are the only group worldwide with this technology. Over the course of this 2-year project we will conduct follow-up experiments to refine this discovery and investigate the feasibility of using this approach to treat human infertility. We are already in negotiations with two medical device manufacturers to licence this technology. We expect that this project will lead to a series of products and technologies that will enter a clinical trial for the treatment of infertility within 2-3 years.Read moreRead less
Seminal Fluid As A Determinant Of Reproductive Health In Women
Funder
National Health and Medical Research Council
Funding Amount
$511,294.00
Summary
Healthy reproductive function is essential for conception and pregnancy. We have discovered that male seminal fluid can influence the female reproductive system after coitus. This project will define the actions of seminal fluid in the cervix and uterus, and the impact on fertility and defence against sexually transmitted infection. The findings will provide new insight on how men contribute to reproductive health in women, and lead to improved treatments for infertility and miscarriage.